Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Janux Therapeutics, Inc. JANX NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$39.80
+164.6%

Janux Therapeutics, Inc. (JANX) is a Biotechnology company in the Healthcare sector, currently trading at $15.04. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is JANX = $40 (+164.6% upside).

Valuation: JANX trades at a trailing Price-to-Earnings (P/E) of -7.9 (S&P 500 average ~25).

Financials: revenue is $10M, +6.4%/yr average growth. Net income is $114M (loss), growing at -30.2%/yr. Net profit margin is -1136.3% (negative). Gross margin is 79.7% (-10.5 pp trend).

Balance sheet: total debt is $22M against $957M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 39.04 (strong liquidity). Debt-to-assets is 2.2%. Total assets: $1.0B.

Analyst outlook: 11 / 13 analysts rate JANX as buy (85%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 93/100 (Pass), Growth 40/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 41/100 (Fail), Future 94/100 (Pass), Income 10/100 (Fail).

$39.80
▲ 164.63% Upside
Average Price Target
Based on 13 Wall Street analysts offering 12-month price targets for Janux Therapeutics, Inc., the average price target is $39.80, with a high forecast of $57.00, and a low forecast of $29.00.
Highest Price Target
$57.00
Average Price Target
$39.80
Lowest Price Target
$29.00

JANX SharesGrow Score Overview

63/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 93/100
Valuation — P/E, PEG, Forward PEG
GROWTH 40/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 41/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — JANX

✓
VALUE Pass
93/100
JANX trades at a trailing Price-to-Earnings (P/E) of -7.9 (S&P 500 average ~25). Forward PEG -0.28 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.89. Analyst consensus target is $40, implying +166% from the current price $15. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
40/100
JANX: +6.4%/yr revenue is, -30.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet JANX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 39.04 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
41/100
JANX: Gross margin is 79.7% (-10.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 41/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 11 / 13 analysts rate JANX as buy (85%). Analyst consensus target is $40 (+166% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
JANX: Net profit margin is -1136.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range12.12-35.34
Volume972.08K
Avg Volume (30D)1.24M
Market Cap$914.91M
Beta (1Y)2.81
Share Statistics
EPS (TTM)-1.83
Shares Outstanding$61.97M
IPO Date2021-06-11
Employees91
CEODavid Alan Campbell
Financial Highlights & Ratios
Revenue (TTM)$10M
Gross Profit$7.97M
EBITDA$-111.6M
Net Income$-113.63M
Operating Income$-157.67M
Total Cash$966.57M
Total Debt$22.14M
Net Debt$-30.2M
Total Assets$1B
Price / Earnings (P/E)-8.2
Price / Sales (P/S)91.49
Analyst Forecast
1Y Price Target$38.00
Target High$57.00
Target Low$29.00
Upside+152.7%
Rating ConsensusBuy
Analysts Covering13
Buy 85% Hold 15% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS47103J1051

Price Chart

Track all markets on TradingView
JANX
Janux Therapeutics, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
12.12 52WK RANGE 35.34

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.70
+1.63%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 HRMY
HRMY
Harmony Biosciences Holdings, Inc.
$29.22
-0.24%
 KROS
KROS
Keros Therapeutics, Inc.
$11.71
+1.39%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 FENC
FENC
Fennec Pharmaceuticals Inc.
$6.50
+4.00%
 MOLN
MOLN
Molecular Partners AG
$4.20
+1.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message